CAY10773 |
| Katalog-Nr.GC47065 |
A derivative of sorafenib
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1648546-79-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
CAY10773 is a derivative of the ferroptosis inducer sorafenib .1 It selectively inhibits proliferation of BEL-7402, MGC803, and T24 bladder cancer cells (IC50s = 5.77, 5.21 and 3.97 µM, respectively) over non-cancerous HCV-29 cells (IC50 = 23.19 µM). CAY10773 induces apoptosis in T24 cells when used at concentrations ranging from 2 to 6 µM but induces ferroptosis at concentrations greater than or equal to 6 µM with 10 hour or longer incubation times. It increases the production of reactive oxygen species (ROS) and decreases the mitochondrial membrane potential in T24 cells. CAY10773 (≥6 µM) also induces autophagy with incubation times longer than eight hours.
1.Chen, J.-N., Li, T., Cheng, L., et al.Synthesis and in vitro anti-bladder cancer activity evaluation of quinazolinyl-arylurea derivativesEur. J. Med. Chem.205112661(2020)
Average Rating: 5 (Based on Reviews and 38 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *